Intensive chemotherapy in myelodysplastic syndromes.
Patients with myelodysplastic syndrome (MDS) who have more than 10% blasts in their bone marrow have a very short survival. Treatment has not improved for these patients for the past 10 years and supportive care alone is still the gold standard. Intensive chemotherapy for poor prognosis MDS has been little tried, but complete remission rates are higher in such studies than in patients with acute myeloid leukaemia (AML) supervening on the MDS. Although these groups may not be comparable, and neither group is representative of the majority of patients with the MDS who are generally older, a case can be made for a randomised prospective study comparing intensive chemotherapy and supportive care alone in poor prognosis MDS. For patients with the myelodysplastic syndrome intensive chemotherapy may carry special risks. The involvement of the whole marrow in the neoplastic clone, and the likelihood of anthracycline resistance are two such hazards which may need to be circumvented.
Hamblin
T J
TJ
Department of Haematology, Royal Bournemouth Hospital, UK.
D000367:Age Factors; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods; D004351:Drug Resistance; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000209:etiology; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000401:mortality; D011379:Prognosis; D012074:Remission Induction; D016019:Survival Analysis
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents